250 related articles for article (PubMed ID: 12152005)
1. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
4. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
6. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
Thijssen HH; Drittij MJ; Vervoort LM; de Vries-Hanje JC
Clin Pharmacol Ther; 2001 Sep; 70(3):292-8. PubMed ID: 11557918
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry.
Werner U; Werner D; Pahl A; Mundkowski R; Gillich M; Brune K
Biomed Chromatogr; 2002 Feb; 16(1):56-60. PubMed ID: 11816012
[TBL] [Abstract][Full Text] [Related]
8. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.
Perini JA; Vianna-Jorge R; Brogliato AR; Suarez-Kurtz G
Clin Pharmacol Ther; 2005 Oct; 78(4):362-9. PubMed ID: 16198655
[TBL] [Abstract][Full Text] [Related]
10. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers.
Fischer TL; Pieper JA; Graff DW; Rodgers JE; Fischer JD; Parnell KJ; Goldstein JA; Greenwood R; Patterson JH
Clin Pharmacol Ther; 2002 Sep; 72(3):238-46. PubMed ID: 12235444
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes.
Karaźniewicz-Łada M; Luczak M; Główka F
Xenobiotica; 2009 Jun; 39(6):476-85. PubMed ID: 19480553
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.
Kirchheiner J; Meineke I; Steinbach N; Meisel C; Roots I; Brockmöller J
Br J Clin Pharmacol; 2003 Jan; 55(1):51-61. PubMed ID: 12534640
[TBL] [Abstract][Full Text] [Related]
14. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790
[TBL] [Abstract][Full Text] [Related]
15. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
Yilmaz N; Erbağci AB; Aynacioğlu AS
Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
[TBL] [Abstract][Full Text] [Related]
17. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.
Martínez C; García-Martín E; Blanco G; Gamito FJ; Ladero JM; Agúndez JA
Br J Clin Pharmacol; 2005 Jan; 59(1):62-9. PubMed ID: 15606441
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
[TBL] [Abstract][Full Text] [Related]
20. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
Transon C; Leemann T; Vogt N; Dayer P
Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
